Last reviewed · How we verify
NCT01209299
Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate
trial testing DNA methylation analysis in Melanoma (Skin) in 80 participants. Completed in 19 February 2012.
19 February 2012
Quick facts
| Lead sponsor | ECOG-ACRIN Cancer Research Group |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 19 January 2012 |
| Primary completion | 19 February 2012 |
| Estimated completion | 19 February 2012 |
Drugs / interventions tested
- DNA methylation analysis
- gene expression analysis
- laboratory biomarker analysis — full drug profile →
Conditions studied
- Melanoma (Skin) — all drugs for Melanoma (Skin) →
Sponsor
ECOG-ACRIN Cancer Research Group
Who can join
Adults 18 to 120, any sex, with Melanoma (Skin). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
RATIONALE: Studying samples of tissue in the laboratory from patients receiving carboplatin and paclitaxel with or without sorafenib tosylate may help doctors learn more about the effects of this treatment on cells. It may also help doctors understand how well patients respond to treatment. PURPOSE: This research study is studying biomarkers in predicting response to chemotherapy in patients with advanced or metastatic melanoma previously treated with carboplatin and paclitaxel with or without sorafenib tosylate.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01209299
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of DNA methylation analysis
Trials testing the same drug.
- NCT05004090 — Emotional Regulation in Children With ND: the Role of Genomic Variation, Proteomic Patterns, and Early Experience · unknown
- NCT01421875 — Biomarker Study of Chemotherapy Resistance and Outcomes in Samples From Older Patients With Acute Myeloid Leukemia · completed
- NCT01149850 — Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma · Phase 2 · completed
- NCT00770471 — ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme · Phase 1 · completed
- NCT00977457 — Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery · Phase 1 · active not recruiting
Other recruiting trials for Melanoma (Skin)
Currently open trials in the same condition.
- NCT06643286 — Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma · NA · recruiting
- NCT06298734 — High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial · NA · recruiting
- NCT05704647 — Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases · Phase 2 · recruiting
- NCT05492682 — START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer · Phase 1 · active not recruiting
- NCT05649683 — Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors · NA · recruiting
Other ECOG-ACRIN Cancer Research Group trials
Trials by the same sponsor.
- NCT07001748 — Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With G · Phase 2, PHASE3 · recruiting
- NCT06526897 — Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Ext · NA · not yet recruiting
- NCT06475989 — Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer · Phase 3 · recruiting
- NCT06084845 — Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for P · Phase 2 · withdrawn
- NCT06319027 — Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Tr · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01209299 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ECOG-ACRIN Cancer Research Group
- Last refreshed: 17 May 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01209299.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing